NCT00676260: Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin |
|
|
| Completed | 2 | 29 | Europe | Pioglitazone, Actos, AD4833, Placebo | Takeda | Diabetes Mellitus | 08/04 | 08/04 | | |
NCT00762736: Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 704 | US, RoW | Pioglitazone and azilsartan, ACTOS®, AD4833, TAK-536, Pioglitazone | Takeda | Diabetes Mellitus | 10/05 | 10/05 | | |
NCT00722917: Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus |
|
|
| Terminated | 2 | 323 | US | TAK-379, Actos, Pioglitazone, AD4833, Placebo | Takeda | Diabetes Mellitus | 04/09 | 04/09 | | |
| Completed | 2 | 40 | Europe | Pioglitazone and insulin, ACTOS®, AD-4833, Insulin | Takeda | Diabetes Mellitus | 06/10 | 06/10 | | |
NCT00443755: Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance |
|
|
| Completed | 2 | 28 | US | metformin, Fortamet, Glucophage, Glucophage Extended Release (XR), Glumetza, Riomet, pioglitazone, Actos, Placebo | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Takeda Pharmaceuticals North America, Inc., National Center for Research Resources (NCRR) | Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome | 08/10 | 08/10 | | |
